UNASSIGNED: e16002 Background: To evaluate @entity1 with @entity957 (SCC) to see is it a primary or metastatic and determine the outcome of @entity1 . METHODS: Fifty-nine @entity1 were identified with parotid SCC through the hospital database, @entity1 ' charts, imaging studies, and computerized notes of the University of Michigan. RESULTS: Fifty @entity1 diagnosed as metastatic SCC of parotid lymph nodes. However, 9 @entity1 diagnosed as primary. Forty seven @entity1 with metastatic SCC treated with surgery and post-operative radiotherapy. The median follow up of these @entity1 was 33 months. The 3-year actuarial cause specific survival was 91%. The 3-year actuarial local recurrence free survival (LRFS) and disease free survival rate were79% and 77% respectively. Positive surgical margin after parotidectomy was the only factor that had statistically significant poor LRFS. CONCLUSIONS: The most common site of the @entity5 was a cutaneous SCC of the face. All @entity1 should be considered for facial sparing radical parotidectomy and adjuvant radiotherapy. Neck dissection or elective neck irradiation for @entity135 is recommended due to high occult LN @entity3 . The addition of chemotherapy or targeted therapy may be beneficial and are points of research. [Table: see text].

XXXX : Is it a primary or secondary?

@entity1 :: ('9606', 'Species') :: ['patients'] @entity135 :: ('MESH:D006258', 'Disease') :: ['ipsilateral neck'] @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor'] @entity957 :: ('MESH:D002294', 'Disease') :: ['parotid squamous cell carcinoma'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity957 :: (MESH:D002294,Disease) :: ['Parotid squamous cell carcinoma']
